mRNA-1982

BIOLOGICAL2 trials

Sponsors

ModernaTX, Inc.

Conditions

Lyme Disease

Phase 1

A Study to Evaluate the Safety and Immunogenicity of mRNA-1975 and mRNA-1982 Against Lyme Disease in Participants 18 Through 70 Years of Age

CompletedNCT05975099

ModernaTX, Inc.Lyme Disease

Start: 2023-07-26End: 2025-05-30Updated: 2026-07-30

Phase 2

A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1982 to Prevent Lyme Disease in Healthy Participants (18 to 70 Years of Age)

Active, not recruitingNCT07561294

ModernaTX, Inc.Lyme Disease

Start: 2026-04-29End: 2028-11-09Updated: 2026-08-03

Related Papers

P-1485. Safety and Immunogenicity of mRNA-1982 and mRNA-1975, mRNA Vaccine Candidates for Prevention of Lyme Disease in Healthy Adults: Interim Results of a Phase 1/2, Randomized, Observer-Blind, Placebo-Controlled, Dose-Ranging Trial

Open Forum Infectious Diseases2026-01-01